Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 12,980 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 12,980 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total value of $235,067.80. Following the sale, the insider directly owned 40,049 shares of the company’s stock, valued at approximately $725,287.39. This represents a 24.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nicola Deidre Petal Greenway also recently made the following trade(s):

• On Monday, August 10th, Nicola Deidre Petal Greenway sold 6,774 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total value of $115,835.40.

Takeda Pharmaceutical Stock Performance

NYSE:TAK traded up $0.32 during midday trading on Wednesday, reaching $18.36. The stock had a trading volume of 3,309,185 shares, compared to its average volume of 3,178,624. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The stock has a market cap of $58.84 billion, a P/E ratio of 54.01 and a beta of -0.08. The firm has a fifty day simple moving average of $16.65 and a two-hundred day simple moving average of $17.16. Takeda Pharmaceutical Co. has a 12-month low of $12.99 and a 12-month high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, July 30th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.17 by $0.30. The company had revenue of $7.50 billion during the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, equities analysts expect that Takeda Pharmaceutical Co. will post 1.5 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on TAK shares. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TAK. Arrowstreet Capital Limited Partnership increased its position in Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares in the last quarter. UBS Group AG lifted its holdings in Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares in the last quarter. Qube Research & Technologies Ltd lifted its stake in shares of Takeda Pharmaceutical by 407.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after buying an additional 1,426,184 shares during the period. Van ECK Associates Corp boosted its position in Takeda Pharmaceutical by 98.4% during the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after acquiring an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its stake in Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after acquiring an additional 880,289 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.